Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Not currently accepting
MonumenTAL-8
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Learn more- Bispecific Antibody
- CAR T Cell
- BCMA
- GPRC5D
- Phase 2
Accepting patients
GCO12F CAR-T
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- CD19
- Phase 1/2
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Not yet accepting
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Accepting patients
iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
Accepting patients
BGB-11417
A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
Cemsidomide (CFT7455)
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more- IKZF1/3
- Phase 1/2
Accepting patients
VICD
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD)
Learn more- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
IMPEDE
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Learn more- Monoclonal Antibody
- CD38
- Phase 2
- Has results
Accepting patients
ISB 1442
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- CD38
- CD47
- Phase 1/2
- Has results
2 hidden based on your filters. Show All